SeaStar Medical Holding Corporation (ICU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SeaStar Medical Holding Corporation (ICU) has a cash flow conversion efficiency ratio of -0.335x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.84 Million) by net assets ($11.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
SeaStar Medical Holding Corporation - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how SeaStar Medical Holding Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SeaStar Medical Holding Corporation (ICU) financial obligations for a breakdown of total debt and financial obligations.
SeaStar Medical Holding Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SeaStar Medical Holding Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Morenzo Abadi Perkasa Tbk Pt
JK:ENZO
|
0.005x |
|
Ranplan Group
ST:RPLAN
|
-0.745x |
|
Megado Minerals Ltd
AU:MEG
|
-0.069x |
|
RKEC Projects Limited
NSE:RKEC
|
0.014x |
|
Revenue Group Bhd
KLSE:0200
|
0.178x |
|
Jwwinvest
WAR:JWW
|
0.191x |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
0.065x |
|
Chemomab Therapeutics Ltd DRC
NASDAQ:CMMB
|
-0.348x |
Annual Cash Flow Conversion Efficiency for SeaStar Medical Holding Corporation (2020–2024)
The table below shows the annual cash flow conversion efficiency of SeaStar Medical Holding Corporation from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see ICU stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-2.18 Million | $-16.01 Million | 7.333x | +888.85% |
| 2023-12-31 | $-13.87 Million | $-10.29 Million | 0.742x | +97.53% |
| 2022-12-31 | $-20.76 Million | $-7.79 Million | 0.375x | -79.33% |
| 2021-12-31 | $-2.82 Million | $-5.11 Million | 1.816x | +2233.07% |
| 2020-12-31 | $-71.58 Million | $-5.57 Million | 0.078x | -- |
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hy… Read more